(RTTNews) - On Monday, Standard BioTools Inc. (NASDAQ: LAB) announced that it has signed a definitive agreement to sell its Microfluidics business to ARCHIMED, an investment firm focused on the healthcare industry.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.